Market Leader Position 23mofang as the leading consumer genetics platform in China with Forbes China recognition, highlighting a strong brand to open conversations with potential enterprise partners, insurers, and healthcare collaborators seeking consumer genetic insights.

Growth Funding Leverage the recent Series B funding of approximately $15.8 million to discuss expansion plans, product development pipelines, and potential co-investment or partnership opportunities with ecosystem players and venture-backed clients.

Data Advantage Emphasize the company’s data-centric mission and life database capability to offer data-driven consumer insights, enabling opportunities for data partnerships, analytics services, and personalized health solutions with consumer brands and pharmaceutical firms.

China Focus Highlight China-specific consumer genetics focus and large addressable market, presenting tailored sales pitches to domestic insurers, employers, and wellness platforms seeking scalable genetic testing and health risk assessment services.

Tech Stack Fit Leverage their technology footprint (Node.js, Nuxt.js/Vue.js, cloud and analytics tools) to propose integration-friendly services, white-labeling, or platform collaborations with tech-enabled health startups and digital health ecosystems.